Skip to search formSkip to main contentSkip to account menu

PROMACE-CytaBOM protocol

Known as: ARA-C/BLEO/CTX/DOX/MTX/PRED/VCR/VP-16, Bleomycin/Cyclophosphamide/Cytarabine/Doxorubicin/Etoposide/Methotrexate/Prednisone/Vincristine, ProMACE-CytaBOM 
National Institutes of Health

Related topics

Related topics

12 relations

Broader (6)

Antineoplastic Combined Chemotherapy ProtocolsBleomycinCyclophosphamideEtoposide
CytarabineDoxorubicinDoxorubicin HydrochloridePrednisone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
The purpose of this article was to evaluate the antitumor effects of a combination chemotherapy program based on ProMACE… 
Highly Cited
1998
Highly Cited
1998
Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.
The down-regulation of multidrug resistance (mdr1) gene expression as detected by competitive reverse transcription-PCR and the… 
1998
1998
Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
BACKGROUND AND OBJECTIVE The use of hematopoietic growth factors in association with chemotherapy in human immunodeficiency virus… 
1998
1998
Treatment of multifocal lymphoma of bone with intensified Promace‐Cytabom chemotherapy and involved field radiotherapy
Primary bone involvement is an unusual extranodal presentation of non‐Hodgkin lymphoma (NHL). The optimal treatment for this… 
1997
1997
Durable remission after aggressive chemotherapy for post-cardiac transplant lymphoproliferation.
A frequently fatal complication of organ transplantation, post-transplant lymphoproliferative disorder (PTLD) develops in 2%-6… 
Highly Cited
1996
Highly Cited
1996
Compound heterozygosity for unstable hemoglobin Genova and beta(o)-thalassemia associated with early onset of thalassemia major syndrome.
We described the case of an infant with compound heterozygozity for a b0-thalassemic mutation and Hemoglobin (Hb) Genova, an… 
1995
1995
Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases.
1995
1995
Effects of Thymostimulin with Combination Chemotherapy in Patients with Aggressive Non‐Hodgkin's Lymphoma: A Report from the Italian Lymphoma Study Group (GISL)
The purpose of this study was to test the efficacy and safety of thymostimulin (TS) administered in addition to conven tional… 
1994
1994
A cooperative study on ProMACE-CytaBOM in aggressive non-Hodgkin's lymphomas.
Chemotherapy using cyclophosphamide, doxorubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate with leucovorin… 
1989
1989
ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma.
ProMACE CytaBOM, a polychemotherapy regimen consisting of cyclophosphamide, doxorubicin, etoposide cytozar, bleomycin… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)